AstraZeneca partners with Daichii Sankyo in potential $6bn cancer drug deal
pharmafile | July 27, 2020 | News story | Research and Development, Sales and Marketing | AstraZeneca, Daiichi Sankyo, partnership, pharma
AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface antigen (TROP) 2-directed DXd antibody drug conjugate (ADC) in the treatment of non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC), it has emerged, in a deal worth a potential $6 billion in total.
AstraZeneca with pay $1 billion up front as part of the deal, with £350 million paid immediately and two further payments of $325 million to be made after 12 and 24 months. On top of this, Daiichi Sankyo will be eligible to receive up to an additional $5 billion in milestone payments, with $1 billion dependent on regulatory successes and $4 billion reserved and contingent upon the fulfilment of future commercial goals.
Both companies will share commercialisation duties worldwide along with associated costs, except in Japan where Daiichi Sankyo will have exclusive rights. As stipulated by the agreement, Daiichi Sankyo will have responsibility for the manufacture and supply of DS-1062.
“DS-1062…has the potential to become a best-in-class TROP2 ADC in multiple tumours, including lung and breast cancers,” explained Sunao Manabe, Representative Director, President and CEO at Daiichi Sankyo. “This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible.”
This is the second time the pair have partnered up in this way, following an agreement back in March 2019 to develop and commercialise Daiichi’s ADC drug Enhertu.
Matt Fellows
Related Content
AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
